Stoke Therapeutics, Inc. is a pharmaceutical company based in the United States that focuses on tackling severe diseases by increasing protein expression through RNA-based medicines. With their proprietary TANGO approach, they develop antisense oligonucleotides (ASOs) to selectively boost protein levels. Their leading compound, STK-001, is currently undergoing clinical trials for treating Dravet syndrome, a severe genetic epilepsy. Stoke Therapeutics operates primarily in the U.S. and has a medium risk rating score of 25.2.